In normal cancer cells and cancer stem cells, 1,25(OH)2D3 signaling starts upon binding with VDR and exerts its anticancer activities by either regulating target gene expression or through non-genomic regulations of different signaling pathways. This evidence concerns the gene VDR and cancer.